are glp-1 receptor agonists banned by wada 2025 Frontiers Could popular GLP-1 drugs change

The regulatory story is not simple, but understanding it is essential for researchers who want to operate within legal frameworks while accessing the compounds they need for their work

Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days

wipe benches

doi: 10.1158/1078-0432.CCR-10-1073 168 HeerenAMKosterBDSamuelsSFernsDMChondronasiouDKenterGGet al

The table below shows options for meeting the U.S